[1] [1] AKHTAR A. The flaws and human harms of animal experimentation[J]. Camb Q Healthc Ethics, 2015, 24(4): 407-419. DOI: 10.1017/S0963180115000079.

[2] [2] BALCOMBE J P. Laboratory environments and rodents' behavioural needs: a review[J]. Lab Anim, 2006, 40(3): 217-235. DOI: 10.1258/002367706777611488.

[3] [3] TEBON P J, WANG B W, MARKOWITZ A L, et al. Drug screening at single-organoid resolutionviabioprinting and interferometry[J]. Nat Commun, 2023, 14(1): 3168. DOI: 10.1038/s41467-023-38832-8.

[4] [4] LEVATO R, DUDARYEVA O, GARCIAMENDEZ-MIJARES C E, et al. Light-based vat-polymerization bioprinting[J]. Nat Rev Meth Primers, 2023, 3: 47. DOI: 10.1038/s43586-023-00231-0.

[5] [5] KANG H W, LEE S J, KO I K, et al. A 3D bioprinting system to produce human-scale tissue constructs with structural integrity[J]. Nat Biotechnol, 2016, 34(3): 312-319. DOI: 10.1038/nbt.3413.

[6] [6] JI S, GUVENDIREN M. Recent advances in bioink design for 3D bioprinting of tissues and organs[J]. Front Bioeng Biotechnol, 2017, 5: 23. DOI: 10.3389/fbioe.2017.00023.

[7] [7] WANG T, HAN Y, WU Z J, et al. Tissue-specific hydrogels for three-dimensional printing and potential application in peripheral nerve regeneration[J]. Tissue Eng Part A, 2022, 28 (3-4): 161-174. DOI: 10.1089/ten.TEA.2021.0093.

[8] [8] XIANG Y, MILLER K, GUAN J A, et al. 3D bioprinting of complex tissuesin vitro: state-of-the-art and future perspectives[J]. Arch Toxicol, 2022, 96(3): 691-710. DOI: 10.1007/s00204-021-03212-y.

[9] [9] TANG M, RICH J N, CHEN S C. Biomaterials and 3D bioprinting strategies to model glioblastoma and the blood-brain barrier[J]. Adv Mater, 2021, 33(5): e2004776. DOI: 10.1002/adma.202004776.

[10] [10] ZHOU L Y, FU J Z, HE Y. A review of 3D printing technologies for soft polymer materials[J]. Adv Funct Mater, 2020, 30(28): 2000187. DOI: 10.1002/adfm.202000187.

[11] [11] U. S. Food and Drug Administration. Novel drug approvals for 2024[EB/OL]. (2024-05-22) [2025-06-05]. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024.

[12] [12] VAN NORMAN G A. Limitations of animal studies for predicting toxicity in clinical trials: is it time to rethink our current approach?[J]. JACC Basic Transl Sci, 2019, 4(7): 845-854. DOI: 10.1016/j.jacbts.2019.10.008.

[13] [13] SCHUSTER B, JUNKIN M, KASHAF S S, et al. Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids[J]. Nat Commun, 2020, 11(1): 5271. DOI: 10.1038/s41467-020-19058-4.

[14] [14] TUNG Y T, CHEN Y C, DERR K, et al. A 3D bioprinted human neurovascular unit model of glioblastoma tumor growth[J]. Adv Healthc Mater, 2024, 13(15): e2302831. DOI: 10.1002/adhm.202302831.

[15] [15] DESIGAUX T, COMPERAT L, DUSSERRE N, et al. 3D bioprinted breast cancer model reveals stroma-mediated modulation of extracellular matrix and radiosensitivity[J]. Bioact Mater, 2024, 42: 316-327. DOI: 10.1016/j.bioactmat.2024.08.037.

[16] [16] TANG M, XIE Q, GIMPLE R C, et al. Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions[J]. Cell Res, 2020, 30 (10): 833-853. DOI: 10.1038/s41422-020-0338-1.

[17] [17] TANG M, TIWARI S K, AGRAWAL K, et al. Rapid 3D bioprinting of glioblastoma model mimicking native biophysical heterogeneity[J]. Small, 2021, 17(15): e2006050. DOI: 10.1002/smll.202006050.

[18] [18] TANG M, QU Y J, HE P X, et al. Heat-inducible CAR-T overcomes adverse mechanical tumor microenvironment in a 3D bioprinted glioblastoma model[J]. Mater Today Bio, 2024, 26: 101077. DOI: 10.1016/j.mtbio.2024.101077.

[19] [19] JOHNSON B N, LANCASTER K Z, HOGUE I B, et al. 3D printed nervous system on a chip[J]. Lab Chip, 2016, 16(8): 1393-1400. DOI: 10.1039/c5lc01270h.

[20] [20] BANERJEE D, IVANOVA M M, CELIK N, et al. Biofabrication of anin-vitrobone model for Gaucher disease[J]. Biofabrication, 2023, 15(4): 045023. DOI: 10.1088/1758-5090/acf95a.

[21] [21] SCARIAN E, BORDONI M, FANTINI V, et al. Patients' stem cells differentiation in a 3D environment as a promising experimental tool for the study of amyotrophic lateral sclerosis[J]. Int J Mol Sci, 2022, 23(10): 5344. DOI: 10.3390/ijms23105344.

[22] [22] ROUSSEL R, STEG P G, MOHAMMEDI K, et al. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: a perspective on glucose-lowering interventions[J]. Diabetes Obes Metab, 2018, 20(2): 238-244. DOI: 10.1111/dom.13033.

[23] [23] ALI A S M, WU D W, BANNACH-BROWN A, et al. 3D bioprinting of liver models: a systematic scoping review of methods, bioinks, and reporting quality[J]. Mater Today Bio, 2024, 26: 100991. DOI: 10.1016/j.mtbio.2024.100991.

[24] [24] NGUYEN D G, FUNK J, ROBBINS J B, et al. Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicityin vitro[J]. PLoS One, 2016, 11(7): e0158674. DOI: 10.1371/journal.pone.0158674.

[25] [25] JANANI G, PRIYA S, DEY S, et al. Mimicking native liver lobule microarchitecturein vitrowith parenchymal and non-parenchymal cells using 3D bioprinting for drug toxicity and drug screening applications[J]. ACS Appl Mater Interfaces, 2022, 14(8): 10167-10186. DOI: 10.1021/acsami.2c00312.

[26] [26] HE J Y, WANG J L, PANG Y, et al. Bioprinting of a hepatic tissue model using human-induced pluripotent stem cell-derived hepatocytes for drug-induced hepatotoxicity evaluation[J]. Int J Bioprint, 2022, 8(3): 581. DOI: 10.18063/ijb.v8i3.581.

[27] [27] DEY S, BHAT A, JANANI G, et al. Microfluidic human physiomimetic liver model as a screening platform for drug induced liver injury[J]. Biomaterials, 2024, 310: 122627. DOI: 10.1016/j.biomaterials.2024.122627.

[28] [28] FERRI N, SIEGL P, CORSINI A, et al. Drug attrition during preclinical and clinical development: understanding and managing drug-induced cardiotoxicity[J]. Pharmacol Ther, 2013, 138(3): 470-484. DOI: 10.1016/j.pharmthera.2013.03.005.

[29] [29] YANG K X, WANG L X, VIJAYAVENKATARAMAN S, et al. Recent applications of three-dimensional bioprinting in drug discovery and development[J]. Adv Drug Deliv Rev, 2024, 214: 115456. DOI: 10.1016/j.addr.2024.115456.

[30] [30] ARAI K, MURATA D, TAKAO S, et al. Drug response analysis for scaffold-free cardiac constructs fabricated using bio-3D printer[J]. Sci Rep, 2020, 10(1): 8972. DOI: 10.1038/s41598-020-65681-y.

[31] [31] IWANAGA S, HAMADA Y, TSUKAMOTO Y, et al. Design and fabrication of mature engineered pre-cardiac tissue utilizing 3D bioprinting technology and enzymatically crosslinking hydrogel[J]. Materials, 2022, 15(22): 7928. DOI: 10.3390/ma15227928.

[32] [32] LIU S T, WANG Z H, CHEN X Y, et al. Multiscale anisotropic scaffold integrating 3D printing and electrospinning techniques as a heart-on-a-chip platform for evaluating drug-induced cardiotoxicity[J]. Adv Healthc Mater, 2023, 12(24): e2300719. DOI: 10.1002/adhm.202300719.

[34] [34] BAI Y X, WANG Z J, HE X L, et al. Application of bioactive materials for osteogenic function in bone tissue engineering[J]. Small Methods, 2024, 8(8): e2301283. DOI: 10.1002/smtd.202301283.

[35] [35] YAN Y F, CHEN H, ZHANG H B, et al. Vascularized 3D printed scaffolds for promoting bone regeneration[J]. Biomaterials, 2019, 190-191: 97-110. DOI: 10.1016/j.biomaterials.2018.10.033.

[36] [36] VEGA S L, KWON M Y, BURDICK J A. Recent advances in hydrogels for cartilage tissue engineering[J]. Eur Cell Mater, 2017, 33: 59-75. DOI: 10.22203/eCM.v033a05.

[37] [37] WENG T T, ZHANG W, XIA Y L, et al. 3D bioprinting for skin tissue engineering: Current status and perspectives[J]. J Tissue Eng, 2021, 12: 20417314211028574. DOI: 10.1177/20417314211028574.

[38] [38] SHI Y, XING T L, ZHANG H B, et al. Tyrosinase-doped bioink for 3D bioprinting of living skin constructs[J]. Biomed Mater, 2018, 13(3): 035008. DOI: 10.1088/1748-605X/aaa5b6.

[39] [39] JIN R H, CUI Y C, CHEN H J, et al. Three-dimensional bioprinting of a full-thickness functional skin model using acellular dermal matrix and gelatin methacrylamide bioink[J]. Acta Biomater, 2021, 131: 248-261. DOI: 10.1016/j.actbio.2021.07.012.

[40] [40] GOLD K A, SAHA B, RAJEEVA PANDIAN N K, et al. 3D bioprinted multicellular vascular models[J]. Adv Healthc Mater, 2021, 10(21): e2101141. DOI: 10.1002/adhm.202101141.

[41] [41] WU X F, CHEN K, CHAI Q, et al. Freestanding vascular scaffolds engineered by direct 3D printing with Gt-Alg-MMT bioinks[J]. Biomater Adv, 2022, 133: 112658. DOI: 10.1016/j.msec.2022.112658.

[42] [42] LPEZ-CARRASCO A, MARTN-VA S, BURGOS-PANADERO R, et al. Impact of extracellular matrix stiffness on genomic heterogeneity in MYCN-amplified neuro-blastoma cell line[J]. J Exp Clin Cancer Res, 2020, 39(1): 226. DOI: 10.1186/s13046-020-01729-1.

[43] [43] REN X X, HUANG M L, WENG W X, et al. Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application[J]. Cell Rep Med, 2023, 4(11): 101277. DOI: 10.1016/j.xcrm.2023.101277.

[44] [44] LUC R, ASSENZA M R, MAIULLARI F, et al. Inhibition of the mTOR pathway and reprogramming of protein synthesis by MDM4 reduce ovarian cancer metastatic properties[J]. Cell Death Dis, 2021, 12(6): 558. DOI: 10.1038/s41419-021-03828-z.

[45] [45] ZHAO Z Y, FENG X Q, WU H J, et al. Construction of a lung cancer 3D culture model based on alginate/gelatin micro-beads for drug evaluation[J]. Transl Lung Cancer Res, 2024, 13 (10): 2698-2712. DOI: 10.21037/tlcr-24-490.

[46] [46] AL SHIHABI A, TEBON P J, NGUYEN H T L, et al. The landscape of drug sensitivity and resistance in sarcoma[J]. Cell Stem Cell, 2024, 31(10): 1524-1542.e4. DOI: 10.1016/j.stem.2024.08.010.

[47] [47] SUN H, SUN L J, KE X D, et al. Prediction of clinical precision chemotherapy by patient-derived 3D bioprinting models of colorectal cancer and its liver metastases[J]. Adv Sci, 2024, 11 (2): e2304460. DOI: 10.1002/advs.202304460.

[48] [48] PERRON U, GRASSI E, CHATZIPLI A, et al. Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer patient-derived xenografts[J]. Nat Commun, 2024, 15 (1): 9139. DOI: 10.1038/s41467-024-53163-y.

[49] [49] LI S, LV J, LI Z, et al. Overcoming multi-drug resistance in SCLC: A synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway[J]. Mol Cance, 2024, 23(1): 243. DOI: 10.1186/s12943-024-02145-1.

[50] [50] HASHIMOTO T, NAKAMURA Y, FUJISAWA T, et al. The SCRUM-MONSTAR cancer-omics ecosystem: striving for a quantum leap in precision medicine[J]. Cancer Discov, 2024, 14(11): 2243-2261. DOI: 10.1158/2159-8290.CD-24-0206.

[54] [54] HERPERS B, EPPINK B, JAMES M I, et al. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors[J]. Nat Cancer, 2022, 3(4): 418-436. DOI: 10.1038/s43018-022-00359-0.

[55] [55] CHOI J, JUNG T Y, KIM J H, et al. Efficacy of recombinantBacillusCalmette-Gurin containing dltA inin vivothree-dimensional bio-printed bladder cancer-on-a-chip andex vivoorthotopic mouse model[J]. Investig Clin Urol, 2023, 64 (3): 296-305. DOI: 10.4111/icu.20220293.

[56] [56] HONG G, KIM J, OH H, et al. Production of multiple cell-laden microtissue spheroids with a biomimetic hepatic-lobule-like structure[J]. Adv Mater, 2021, 33(36): 2102624. DOI: 10.1002/adma.202102624.

[57] [57] LOPEZ M A, HUTTER L, PAGIN E, et al.In vivoefficacy proof of concept of a large-size bioprinted dermo-epidermal substitute for permanent wound coverage[J]. Front Bioeng Biotechnol, 2023, 11: 1217655. DOI: 10.3389/fbioe.2023.1217655.

[58] [58] LIU Y, ZHANG Y F, MEI T X, et al. hESCs-derived early vascular cell spheroids for cardiac tissue vascular engineering and myocardial infarction treatment[J]. Adv Sci, 2022, 9(9): e2104299. DOI: 10.1002/advs.202104299.

[59] [59] JIANG Z R, JIN B, LIANG Z, et al. Liver bioprinting within a novel support medium with functionalized spheroids, hepatic vein structures, and enhanced post-transplantation vascularization[J]. Biomaterials, 2024, 311: 122681. DOI: 10.1016/j.biomaterials.2024.122681.

[60] [60] SUN Y Y, HUO Y Y, RAN X Y, et al. InstantTracheareconstruction using 3D-bioprintedC-shape biomimeticTracheabased on tissue-specific matrix hydrogels[J]. Bioact Mater, 2023, 32: 52-65. DOI: 10.1016/j.bioactmat.2023.09.011.

[61] [61] SUN Z W, YUE X L, LIU L, et al. Bioprinted Notch ligand to function as stem cell niche improves muscle regeneration in dystrophic muscle[J]. Int J Bioprint, 2023, 9(3): 711. DOI: 10.18063/ijb.711.

[62] [62] SUN B B, LIAN M F, HAN Y, et al. A 3D-Bioprinted dual growth factor-releasing intervertebral disc scaffold induces nucleus pulposus and annulus fibrosus reconstruction[J]. Bioact Mater, 2020, 6(1): 179-190. DOI: 10.1016/j.bioactmat.2020.06.022.

[63] [63] XU Z Y, HUANG J J, LIU Y, et al. Extracellular matrix bioink boosts stemness and facilitates transplantation of intestinal organoids as a biosafe Matrigel alternative[J]. Bioeng Transl Med, 2022, 8(1): e10327. DOI: 10.1002/btm2.10327.

[64] [64] NANMO A, YAN L, ASABA T, et al. Bioprinting of hair follicle germs for hair regenerative medicine[J]. Acta Biomater, 2023, 165: 50-59. DOI: 10.1016/j.actbio.2022.06.021.

[65] [65] NG W L, GOH G L, GOH G D, et al. Progress and opportunities for machine learning in materials and processes of additive manufacturing[J]. Adv Mater, 2024, 36(34): e2310006. DOI: 10.1002/adma.202310006.